Bone Tumour, Gynecological Tumors, Lymphoma, Mammary Cancer
Conditions
Brief summary
The purpose of the trail is to evaluate the efficacy and safety of PEG-rhG-CSF in primary prophylaxis and secondary prophylaxis of neutropenia after chemotherapy.
Interventions
DRUGPEG-rhG-CSF
Sponsors
Peking University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Patients with age between 18 and 70 years. 2. Breast cancer, lymphoma, bone tumor or Gynecologic tumor patients. 3. With multi-cycle chemotherapy. 4. With III/IV degree neutropenia after the last cycle of chemotherapy and plans to use the same regimen in the subsequent cycles.FN risk of the chemotherapy regimens is ≥20%，or 10%≤FN risk\<20% and has high risk factors associated with FN. 5. KPS score≥ 70. 6. Expected to survive more than 3 months. 7. No hematologic system disease and ANC≥1.5×10E9/L, PKT≥80×10E9/L, Hb≥ 75g/L, WBC≥3×10E9/L, and no bleeding tendency. 8. Written informed consent are acquired. -
Exclusion criteria
1. With infection or systemic antibiotic therapy 72h before chemotherapy. 2. With any abnormal hematopoietic function. 3. Received transplantation within 3 months. 4. Suffered from other malignant tumor or brain metastases. 5. TBIL, ALT,AST \> 2.5×ULN; if it were caused by liver metastases, TBIL, ALT,AST \>5×ULN. 6. Cr \>1.5 ×ULN. 7. Sensitive to the product or other genetically engineered biological products from Escherichia coli strains. 8. Mental or nervous system disorders. 9. Refused to accept contraceptive measures. 10. Other situations that investigators consider as contra-indication for this study. \-
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of febrile neutropenia (FN) | 30days after PEG-rhG-CSF administration |
Countries
China
Contacts
Primary ContactJun Zhu, MD
Outcome results
None listed